Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Opens European Sales Office in the Netherlands

NEW YORK, Sept 27 – Chip-maker Nanogen (Nasdaq: NGEN) said Wednesday that it has created Nanogen Europe to extend its marketing and sales efforts throughout the continent.

San Diego-based Nanogen, which only recently began marketing its NanoChip system to scientists and genomics laboratories for single-nucleotide polymorphism scoring, made its first commercial sale to French life sciences company Aventis (NYSE: AVE) in June. And a week ago it sold the system to German food additives company SKW Nature Products.

Howard Birndorf, chairman and CEO of Nanogen said in a statement that the new unit was created because he sees Europe as “a potentially important market.”

Roderik van den Bogaard, formerly of Molecular Dynamics and Spectra Physics, has been named managing director of the company’s wholly owned subsidiary based in Helmond, the Netherlands.

Nanogen was up 1/16, or 0.33 percent, at 18 3/4 in afternoon trading.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.